{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Grade 1"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"}],"title":"Grade 2"},{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"56"}],"title":"Grade 3"},{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"25"}],"title":"Grade 4"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Grade 5"}],"title":"All Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"Grade 1"},{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}],"title":"Grade 2"},{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"52"}],"title":"Grade 3"},{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"}],"title":"Grade 4"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Grade 5"}],"title":"Reported as Definitely, Probably, or Possibly Related to Protocol Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"Common Terminology Criteria for Adverse Events (version 4.0 before 4-1-2018; then version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data provided is in this outcome measure; see Adverse Events Module for specific adverse event data.","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible participants who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 8 years.","title":"Frequency of Highest Grade Adverse Event Per Participant","type":"SECONDARY","unitOfMeasure":"Participants"}